Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisinicline for long-term smoking and vaping cessation
NCT06435221Phase 3Completed
- Sponsor
- Achieve Life Sciences
- Start
- May 2024
- Primary completion
- Sep 2025
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cytisinicline in Tobacco Use Disorder (TUD) and nicotine dependence, sponsored by Achieve Life Sciences. Primary endpoint: Treatment Emergent Serious Adverse Events at 52 weeks. Started May 2024; status: completed.
02
Drugs
cytisinicline
03
Conditions
Tobacco Use Disorder (TUD)nicotine dependence
Beyond the preview
Go deeper on NCT06435221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435221.